CureVac N.V. (FRA:5CV)
3.870
-0.080 (-2.03%)
Jun 5, 2025, 6:47 PM CET
CureVac Revenue
CureVac had revenue of 893.00K EUR in the quarter ending March 31, 2025, a decrease of -92.78%. This brings the company's revenue in the last twelve months to 523.70M, up 787.60% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
523.70M
Revenue Growth
+787.60%
P/S Ratio
1.67
Revenue / Employee
579.31K
Employees
983
Market Cap
875.04M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
CureVac News
- 16 days ago - CureVac BV reports Q1 results - Seeking Alpha
- 16 days ago - CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Wallstreet:Online
- 16 days ago - CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Accesswire
- 16 days ago - CureVac Unveils Q1 2025 Financial Results & Business Updates! - Wallstreet:Online
- 16 days ago - EQS-News: CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Wallstreet:Online
- 20 days ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Wallstreet:Online
- 20 days ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Accesswire
- 4 weeks ago - BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion - Benzinga